EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression

Duminduni Hewa Angappulige, Nupam P Mahajan, Kiran Mahajan

Trends in Cancer · 2024

DOI: 10.1016/j.trecan.2024.01.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024. Verfasst von Duminduni Hewa Angappulige und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urologic Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA; Department of Surgery, Washington University in St. Louis…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Department of Defense Prostate Cancer Research Program, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) is immunosuppressive and refractory to immunotherapy. Infiltration of myeloid-derived suppressor cells (MDSCs) and senescent-like neutrophils and T cell exhaustion are observed in the tumor microenvironment (TME) following androgen receptor (AR) antagonism with antiandrogens or androgen ablation. De novo post-translational acetylation of the AR, HOXB13, and H2A at K609, K13, and K130, respectively, and phosphorylation of H4 at Y88 have emerged as key epigenetic modifications associated with castration-resistant PC (CRPC). The resulting chromatin changes are integrated into cellular processes via phosphorylation of the AR, ACK1, ATPF1A, and SREBP1 at Y267, Y284, Y243/Y246, and Y673/Y951, respectively. In this review, we discuss how these de novo epigenetic alterations drive resistance and how efforts aimed at targeting these regulators may overcome immune suppression observed in PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansReceptors, AndrogenPhosphorylationAndrogen AntagonistsEpigenesis, GeneticTumor Microenvironment

Stichwörter der Autor:innen

chromatinepigeneticsimmune suppressionprostate cancertestosterone

Substanzen

Receptors, AndrogenAndrogen Antagonists

Autor:innen und Institutionen

  • Division of Urologic Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA; Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA.
  • Division of Urologic Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA; Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA; Siteman Cancer Center, Washington Universi…

Förderung

  • NCI NIH HHS
  • Department of Defense Prostate Cancer Research Program
  • National Cancer Institute
  • National Institutes of Health
  • U.S. Department of Defense

Zitieren

APA

Angappulige, D. H., Mahajan, N. P., & Mahajan, K. (2024). Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression. Trends in Cancer. https://doi.org/10.1016/j.trecan.2024.01.004

Vancouver

Angappulige DH, Mahajan NP, Mahajan K. Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression. Trends in Cancer. 2024. doi:10.1016/j.trecan.2024.01.004

BibTeX
@article{Angappulige2024,
  author = {Angappulige, Duminduni Hewa and Mahajan, Nupam P and Mahajan, Kiran},
  title = {Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression},
  journal = {Trends in Cancer},
  year = {2024},
  doi = {10.1016/j.trecan.2024.01.004}
}
Kostenlos starten →